We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Based in New Jersey, Becton, Dickinson and Company (BDX - Free Report) is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. These products are used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public.
Currently, Becton, Dickinson has a Zacks Rank #3 (Hold) but that could change following its third-quarter fiscal 2016 earnings report which has just released. We have highlighted some of the key details from the just-released announcement below:
Earnings: Becton, Dickinson’s adjusted earnings of $2.35 per share beat the Zacks Consensus Estimate by 16 cents and increased 19.5% year-over-year on a currency-neutral basis.
Revenues: Adjusted revenues amounted to $3.20 billion, up 3.9% from the year-ago quarter on a comparable currency-neutral basis. Revenues beat the Zacks Consensus Estimate of $3.19 billion.
Key Stats: BD Medical generated revenues of $2.24 billion, up 3% on a year-over-year basis. BD Lifesciences generated revenues of $963 million, up 6% from the year-ago quarter. On a comparable basis, adjusted U.S. revenues increased 3.4%. International revenues increased 4.6% on a currency-neutral basis in the reported quarter.
Major Factors: BD Medical’s year over year growth reflects strong performance in the Medication Management Solutions and Diabetes Care units, and solid growth in the Medication and Procedural Solutions unit. Revenue growth in the BD Lifesciences segment reflects strong performance in the Diagnostic Systems and Preanalytical Systems units, and modest growth in the Biosciences unit.
Stock Price: Following the earnings release, share prices did not show any movement in the pre-market trading session.
Check back later for our full write up on this Becton, Dickinson and Company earnings report later!
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Becton, Dickinson (BDX) Beats Q3 Earnings & Revenues
Based in New Jersey, Becton, Dickinson and Company (BDX - Free Report) is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. These products are used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public.
Currently, Becton, Dickinson has a Zacks Rank #3 (Hold) but that could change following its third-quarter fiscal 2016 earnings report which has just released. We have highlighted some of the key details from the just-released announcement below:
Earnings: Becton, Dickinson’s adjusted earnings of $2.35 per share beat the Zacks Consensus Estimate by 16 cents and increased 19.5% year-over-year on a currency-neutral basis.
Revenues: Adjusted revenues amounted to $3.20 billion, up 3.9% from the year-ago quarter on a comparable currency-neutral basis. Revenues beat the Zacks Consensus Estimate of $3.19 billion.
Key Stats: BD Medical generated revenues of $2.24 billion, up 3% on a year-over-year basis. BD Lifesciences generated revenues of $963 million, up 6% from the year-ago quarter. On a comparable basis, adjusted U.S. revenues increased 3.4%. International revenues increased 4.6% on a currency-neutral basis in the reported quarter.
BECTON DICKINSO Price and EPS Surprise
BECTON DICKINSO Price and EPS Surprise | BECTON DICKINSO Quote
Major Factors: BD Medical’s year over year growth reflects strong performance in the Medication Management Solutions and Diabetes Care units, and solid growth in the Medication and Procedural Solutions unit. Revenue growth in the BD Lifesciences segment reflects strong performance in the Diagnostic Systems and Preanalytical Systems units, and modest growth in the Biosciences unit.
Stock Price: Following the earnings release, share prices did not show any movement in the pre-market trading session.
Check back later for our full write up on this Becton, Dickinson and Company earnings report later!
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>